Second positive phase 3 trial adds to growing body of evidence for WINREVAIR, an activin signaling inhibitor therapy that targets an underlying cause of PAH RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback